Sunil Kumar/LinkedIn
Dec 17, 2025, 23:37
Sunil Kumar: Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024)
Sunil Kumar, Entrepreneur of Medifit Devices LLP, shared a post on LinkedIn:
“Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024).
Rare diseases may affect smaller patient populations, but strong science, high unmet need, and long term therapy adoption continue to translate into meaningful revenues. From enzyme replacement therapies to advanced coagulation factors, these products underline the commercial strength of rare disease portfolios.
The list highlights reported 2024 revenues along with primary approved indications across areas such as amyloidosis, hemophilia, and inherited metabolic disorders.”
Stay updated with Hemostasis Today.
-
Jun 12, 2026, 07:29Tuba Atahan: The Red Thread Linking Patients Families and Progress at EHA2026
-
Jun 12, 2026, 07:19Amber Yates: Learning Connecting and Showing Up for Patients at EHA2026
-
Jun 12, 2026, 07:03Tomás Navarro: Building the Future of Hematology Through Mentorship at EHA2026
-
Jun 12, 2026, 06:53Maria Marketou: Delighted to Announce the Launch of Greece’s 1st Clonal Hematopoiesis Cardio-Hematology Outpatient Clinic
-
Jun 12, 2026, 04:58Pall T. Onundarson: Discussion at NEQAS Revives Interest in Precision Warfarin Monitoring
-
Jun 12, 2026, 04:38Louise St. Germain Bannon: We Can’t Wait to See What Shows Up at The ISTH Hub
-
Jun 12, 2026, 04:31Andrea Van Beek: Anticoagulation and Thrombosis Services Now Available to Medi-Cal Patients in Tulare
-
Jun 12, 2026, 04:24Robert Sidonio: Honor to Have a Detailed Discussion with George Fritsma on the 100 years of VWD
-
Jun 11, 2026, 23:56Francesco Tannura: Here’s a Graphical Summary of Our Latest Work about CAT